These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 9020492

  • 21. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W.
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [Abstract] [Full Text] [Related]

  • 22. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
    Huddart SN, Mann JR, Gornall P, Pearson D, Barrett A, Raafat F, Barnes JM, Wallendsus KR.
    J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
    [Abstract] [Full Text] [Related]

  • 23. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
    Suurmeijer AJ, Oosterhuis JW, Marrink J, De Bruin HW, Schraffordt Koops H, Sleijfer DT, Fleuren GJ.
    Oncodev Biol Med; 1983 Apr; 4(4):289-308. PubMed ID: 6188132
    [Abstract] [Full Text] [Related]

  • 24. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2001 May 01; 19(9):2534-41. PubMed ID: 11331333
    [Abstract] [Full Text] [Related]

  • 25. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
    Keskin S, Ekenel M, Başaran M, Bavbek S.
    Am J Clin Oncol; 2012 Aug 01; 35(4):369-72. PubMed ID: 22814307
    [Abstract] [Full Text] [Related]

  • 26. [Case report of a non-seminomatous testicular neoplasm indicating marked efficacy of a combination chemotherapy of VBL, ACTD, BLM, CDDP and EX (VAB-4 combination therapy)].
    Hayashi M, Ebihara K, Urano E.
    Gan To Kagaku Ryoho; 1984 Dec 01; 11(12 Pt 2):2775-7. PubMed ID: 6210063
    [Abstract] [Full Text] [Related]

  • 27. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy].
    Riedinger JM, Eche N, Chevreau C, Fargeot P.
    Ann Biol Clin (Paris); 2008 Dec 01; 66(5):523-30. PubMed ID: 18957341
    [Abstract] [Full Text] [Related]

  • 28. AFP and HCG in germ cell tumors.
    Bassetto MA, Franceschi T, Lenotti M, Parise G, Pancheri F, Sabbioni R, Zaninelli M, Cetto GL.
    Int J Biol Markers; 1994 Dec 01; 9(1):29-32. PubMed ID: 7519651
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Primary intracranial malignant germ cell tumor associated with abnormal high value of alpha-fetoprotein and human chorionic gonadotropin].
    Nishiyama K, Nishida K, Kusaka K, Morizumi H.
    No Shinkei Geka; 1987 Dec 01; 15(12):1337-42. PubMed ID: 2452372
    [Abstract] [Full Text] [Related]

  • 32. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
    Massard C, Kramar A, Beyer J, Hartmann JT, Lorch A, Pico JL, Rosti G, Droz JP, Fizazi K.
    Ann Oncol; 2013 Feb 01; 24(2):322-328. PubMed ID: 23104726
    [Abstract] [Full Text] [Related]

  • 33. Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.
    van der Gaast A, Hoekstra JW, Croles JJ, Splinter TA.
    J Urol; 1991 Apr 01; 145(4):829-31. PubMed ID: 1706441
    [Abstract] [Full Text] [Related]

  • 34. [False-positive elevation of alpha-fetoprotein during induction chemotherapy in patients with testicular cancer].
    Hida S, Kawakita M, Oishi K, Okada Y, Takeuchi H, Okada K, Yoshida O.
    Hinyokika Kiyo; 1986 Dec 01; 32(12):1859-66. PubMed ID: 2435135
    [Abstract] [Full Text] [Related]

  • 35. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
    Price P, Hogan SJ, Horwich A.
    Eur J Cancer; 1990 Apr 01; 26(4):450-3. PubMed ID: 1694086
    [Abstract] [Full Text] [Related]

  • 36. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.
    Stoter G, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CP, Spaander P, de Pauw M, Sylvester R.
    J Clin Oncol; 1986 Aug 01; 4(8):1199-206. PubMed ID: 2426419
    [Abstract] [Full Text] [Related]

  • 37. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ.
    J Natl Cancer Inst; 1993 Nov 17; 85(22):1828-35. PubMed ID: 7693955
    [Abstract] [Full Text] [Related]

  • 38. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980.
    Nørgaard-Pedersen B, Schultz HP, Arends J, Brincker H, Krag Jacobsen G, Lindeløv B, Rørth M, Svennekjaer IL.
    Acta Radiol Oncol; 1984 Nov 17; 23(4):287-94. PubMed ID: 6208749
    [Abstract] [Full Text] [Related]

  • 39. Chemotherapy of disseminated seminoma.
    Einhorn LH, Williams SD.
    Cancer Clin Trials; 1980 Nov 17; 3(4):307-13. PubMed ID: 6159120
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.